. 2012 Apr 10;40(6):1443–1449. doi: 10.1183/09031936.00010612

Table 2– Risk of progression to tuberculosis (TB) within 2 yrs for QuantiFERON®-TB Gold In-Tube (QFT-GIT)-positive and -negative subjects.

	Case source cohort n	TB within 2 yrs^# n	Incidence of TB within 2 yrs per 100000 population	Expected QFT-GIT positivity at entry^¶ n (%)	Estimated risk of progression to TB per 100000 population⁺ (95% credibility interval)
	Case source cohort n	TB within 2 yrs^# n	Incidence of TB within 2 yrs per 100000 population	Expected QFT-GIT positivity at entry^¶ n (%)	QFT-GIT positive	QFT-GIT negative
Total	26317	30	114	5306 (20)	467 (314–603)	25 (0–64)
Sex
Female	13766	15	109	2619 (19)	473 (318–611)	24 (0–60)
Male	12504	15	120	2691 (22)	460 (310–595)	27 (0–68)
Age yrs
18–24	7877	6	76	1048 (13)	473 (318–611)	15 (0–39)
25–34	12797	16	125	2913 (23)	453 (305–586)	28 (0–72)
≥35	5643	8	142	1339 (24)	493 (332–638)	33 (0–83)
TB incidence in the country of origin cases per 100000 population
<100	13799	12	87	2208 (16)	456 (307–589)	18 (0–46)
100–199	7231	12	166	1708 (24)	590 (397–762)	38 (0–97)
≥200	5040	6	119	1278 (25)	386 (259–499)	28 (0–71)

QFT-GIT is manufactured by Cellestis (Carnegie, Australia). ^#: based on surveillance data from Monitoring for Screening of Immigrants and the Netherlands Tuberculosis Register; ^¶: number estimated based on QFT-GIT-positive prevalence in base cohort as presented in table 1; ⁺: based on Bayesian statistics for posterior distribution resulted in a median (95% credibility interval) sensitivity for QFT-GIT of 83% (56–100%).